Related references
Note: Only part of the references are listed.Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder
Helena A. Gaspar et al.
TRANSLATIONAL PSYCHIATRY (2019)
Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
John F. Greden et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2019)
Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel
Chad Bousman et al.
CURRENT OPINION IN PSYCHIATRY (2019)
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
Samuel T. Wilkinson et al.
DRUG DISCOVERY TODAY (2019)
Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials
Chad A. Bousman et al.
PHARMACOGENOMICS (2019)
Polygenic risk scoring and prediction of mental health outcomes
John S. Anderson et al.
CURRENT OPINION IN PSYCHOLOGY (2019)
A scientometric review of genome-wide association studies
Melinda C. Mills et al.
COMMUNICATIONS BIOLOGY (2019)
Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies
Chiara Fabbri et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2018)
Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility
Paul Bradley et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2018)
Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials
Chiara Fabbri et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2018)
Cardiovascular disease: The rise of the genetic risk score
Joshua W. Knowles et al.
PLOS MEDICINE (2018)
The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants
Alessandro Serretti
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2018)
Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder
Erik J. Groessl et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
Alejandra Maciel et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2018)
Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores
Kristi Laell et al.
GENETICS IN MEDICINE (2017)
Escitalopram plasma levels and antidepressant response
Vincenzo Florio et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)
Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
M. Verbelen et al.
PHARMACOGENOMICS JOURNAL (2017)
Pharmacogenetics of antidepressant response: A polygenic approach
Judit Garcia-Gonzalez et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2017)
Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial
Lindsay S. Elliott et al.
PLOS ONE (2017)
Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: A qualitative study
Siew Ching Ho et al.
PLOS ONE (2017)
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial
Victor Perez et al.
BMC PSYCHIATRY (2017)
Genetic Misdiagnoses and the Potential for Health Disparities
Arjun K. Manrai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report
Ajeet B. Singh
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2015)
Clinical applications of CYP genotyping in psychiatry
Edoardo Spina et al.
JOURNAL OF NEURAL TRANSMISSION (2015)
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996-2013
David A. Mrazek et al.
PSYCHIATRIC SERVICES (2014)
Prevalence of treatment-resistant depression in primary care: cross-sectional data
Laura Thomas et al.
BRITISH JOURNAL OF GENERAL PRACTICE (2013)
Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism
Stefano Porcelli et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients
C Charlier et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2002)